Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
The Motley Fool December 26, 2006 Brian Lawler	2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year.
The Motley Fool July 21, 2006 Brian Lawler	Amgen's Little Helpers Sluggish earnings are offset by promising drugs in the pipeline. The bottom line with Amgen is that it is one of the best-run biotechs, period. Investors, take note.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
The Motley Fool July 12, 2004 Ben McClure	Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool August 26, 2009 Brian Orelli	Amgen Falls Back on the Future Instead of the TREAT trial for Aranesp, Amgen's new cherry is Prolia's potential to treat cancer patients, for which Amgen could get marketing approval next year.
The Motley Fool April 24, 2007 Brian Lawler	Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices.
The Motley Fool January 7, 2010 Brian Orelli	Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
BusinessWeek January 14, 2010 Rob Waters	Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology.
The Motley Fool November 9, 2006 Karl Thiel	The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note.
The Motley Fool May 27, 2009 Brian Orelli	A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452.
The Motley Fool April 21, 2011 Luke Timmerman	Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis.
The Motley Fool January 29, 2007 Brian Lawler	No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors.
BusinessWeek June 4, 2007 Gene G. Marcial	Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled.
The Motley Fool July 21, 2005 Tom Taulli	Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey.
The Motley Fool March 25, 2010 Brian Orelli	More Than $5.3 Billion in Revenue Under Attack After dealing with the FDA, Amgen and J&J now have to deal with the Centers for Medicare & Medicaid Services.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool November 19, 2010 Brian Orelli	One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool January 26, 2010 Brian Orelli	Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010.
The Motley Fool February 29, 2008 Brian Lawler	Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs.
The Motley Fool October 25, 2011 Brian Orelli	Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway.
The Motley Fool February 9, 2011 Luke Timmerman	Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"?
The Motley Fool October 29, 2007 Brian Lawler	Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader.
The Motley Fool September 28, 2006 Brian Lawler	Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note.
The Motley Fool October 20, 2005 Brian Gorman	Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors.
The Motley Fool June 7, 2007 Brian Lawler	Acquisitive Amgen The biotech behemoth acquires Ilypsa and Alantos Pharmaceuticals. The all-cash deals for both companies gives Amgen several mid-stage drug candidates to beef up its drug pipeline.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
BusinessWeek January 29, 2007 Arlene Weintraub	More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl.
The Motley Fool July 30, 2007 Brian Lawler	Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
The Motley Fool February 9, 2010 Brian Orelli	Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.
The Motley Fool June 28, 2004 Alyce Lomax	Is Amgen's Engine Stalled? Amgen slipped in today's trading session after it said that an experimental drug for advanced cases of Parkinson's disease didn't meet its primary end point in a recent clinical trial.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
The Motley Fool January 28, 2008 Brian Lawler	A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.
BusinessWeek September 30, 2009 Arlene Weintraub	J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool August 9, 2010 Luke Timmerman	Affymax Lives to Fight Another Day Affymax takes on Amgen with its anemia drug.
The Motley Fool April 20, 2010 Jim Mueller	Better, Targeted Drugs, Dead Ahead Personalized medicine is becoming a reality that will help patients, companies, and investors.
The Motley Fool October 19, 2010 Brian Orelli	When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday.
The Motley Fool October 21, 2004 W.D. Crotty	One Value-Priced Biotech Giant Amgen is a growing cash machine selling at the market's multiple to earnings.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.